An update from Valion Bio ( ($VBIO) ) is now available.
On June 17, 2026, Valion Bio, Inc. issued 250 shares of its Series B Non-Voting Convertible Preferred Stock at $1,000 per share and a warrant to purchase 156,026 shares of common stock at an exercise price of $0.616280 per share to 3i, LP, for total proceeds of $250,000. This transaction followed an April 29, 2025 Securities Purchase Agreement originally with another investor for up to $8.4 million, which was assigned to 3i on December 9, 2025 and subsequently amended, with the latest issuance executed as an unregistered private offering under exemptions to U.S. securities registration rules, further advancing Valion Bio’s staged equity financing strategy.
Spark’s Take on VBIO Stock
According to Spark, TipRanks’ AI Analyst, VBIO is a Neutral.
The score is primarily constrained by very weak financial performance (shrinking revenue, persistent losses, negative cash flow, and significant balance-sheet erosion). Technicals are mixed but generally pressured by longer-term downtrends, while valuation is hard to support due to negative earnings and no dividend data.
To see Spark’s full report on VBIO stock,
click here.
More about Valion Bio
Valion Bio, Inc., formerly known as Tivic Health Systems, Inc., operates in the biotechnology sector and accesses capital markets through issuances of preferred stock and related warrants. The company structures financing via convertible preferred securities that can be exchanged into common stock, reflecting a focus on equity-based funding to support its corporate activities and growth initiatives.
Average Trading Volume: 287,881
Technical Sentiment Signal: Sell
Current Market Cap: $1.79M
Find detailed analytics on VBIO stock on TipRanks’ Stock Analysis page.
